Shark Tank India Season 2: Namita Thapar is one of the judges of the popular reality show and she always keep an eye on healthcare products. She is also an Executive Director in Emcure Pharmaceuticals Limited. On 10 January, she invested in Ayusynk, the wireless digital stethoscope company. Peyush Bansal also offered them a deal but Namita Thapar convinced to invest in their company single handedly. She said that she has experience in healthcare products and she loves to support people who work for healthcare. Today, she took to twitter to share her concern about low technology in healthcare products.
Shark Tank India Season 2 judge Namita Thapar shared statistics on Twitter
Namita Thapar shared a post and wrote, “Healthcare is my passion and expertise. Ayusynk deal demonstrated a big issue in our country, the lack of 3 A's - lack of awareness, access & affordability of quality healthcare in the interiors of our country & the number of lives lost due to this.”
She further added some data and wrote, “Check out these shocking statistics;
1. 45% of recorded deaths in 2020 were due to lack of medical care access.
2. 69% of hospital beds in India are concentrated in urban areas where as 64% population is concentrated in rural areas. 3. India has 0.934 allopathic doctors per 1000 patients, less than half of developed countries like US which has 2.5 doctors per 1000 patients.
This is a sad reality & we need to do something about this... soon!
I hope we as investors & entrepreneurs continue supporting startups like Ayusynk and others that use technology to address this massive gap, they are truly the need of the hour!”
However, Ayusynk was giving 4% equity but when Namita offered 3% then they locked the deal for 3.5% equity.
Also Read: Pop star Rihanna congratulates RRR team after losing Golden Globe to Naatu Naatu; Ram Charan’s wife Upasana Konidela reacts
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.